


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (canceled).
2. (canceled).
- 3.-67. (canceled).

68. (previously presented) A compound represented by the following formula (I-B):



wherein R¹, R², R³ and R⁴ each independently represents (1) C1-8 alkyl, (2) C2-8 alkenyl, (3) a halogen atom, (4) trihalomethyl, (5) Cycl, (6) -OR⁶, or (7) C1-8 alkyl substituted with -OR⁶ or Cycl;

R⁶ represents (1) a hydrogen atom, (2) C1-8 alkyl, (3) C2-8 alkenyl, (4) Cycl, (5) methyl substituted with 1 to 3 halogen, or (6) C1-8 alkyl substituted with Cycl;

Cycl represents a C3-10 monocyclic or bicyclic carbocyclic group;

G represents a bond,

K and M each independently represents (1) a bond, (2) C1-8 alkylene, or (3) C2-8 alkenylene;

L represents a bond or an oxygen atom;

Ring A represents a C3-10 monocyclic or bicyclic carbocyclic group;

Ring B represents a C3-10 monocyclic or bicyclic carbocyclic group or a three- to ten-membered monocyclic or bicyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s);

Ring D represents a C3-10 monocyclic carbocyclic group or a three- to ten-membered monocyclic heterocyclic group which contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s);

Ring E represents a C3-7 monocyclic carbocyclic group;

p, q, r and s each independently represents 0 or an integer of from 1 to 3,

in which R¹s are the same or different when p represents 2 or more; R²s are the same or different when q represents 2 or more; R³s are the same or different when r represents 2 or more; and R⁴s are the same or different when s represents 2 or more, respectively;

t represents 0 or 1; and

R⁵ represents (1) a hydrogen atom or (2) C1-8 alkyl, or a salt thereof.

69. (currently amended) A pharmaceutical composition comprising the compound according to claim 68, or a salt thereof ~~or a prodrug thereof~~ and a pharmaceutically acceptable carrier.

70. (previously presented) The pharmaceutical composition according to claim 69, which is an LPA receptor antagonist.

71. (previously presented) The pharmaceutical composition according to claim 70, wherein the LPA receptor is EDG-2 receptor.

72. (currently amended) The pharmaceutical composition according to claim 71, which is an agent for ~~prevention and/or treatment~~ for urinary system disease.

73. (canceled).

74. (currently amended) A method for ~~prevention and/or treatment~~ of diseases referred from EDG-2, which comprises administering an effective amount of the compound according to claim 68, or a salt thereof ~~or a prodrug thereof~~ to a mammal.

75. (currently amended): The method for ~~prevention and/or treatment~~ according to claim 74, wherein the disease referred from EDG-2 is urinary system disease.

Claims 76-80. (canceled).